anti-inflammatoty and immuno-therapy - versus control - for COVID-19 mild to moderate pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.67 [0.48, 0.93]< 10%6 studies (6/-)99.1 %some concernnot evaluable moderatecrucial-
death or transfer to ICU 1.07 [0.73, 1.57]< 10%1 study (1/-)36.6 %highnot evaluable lowcrucial-
deaths 0.73 [0.59, 0.92]< 10%12 studies (12/-)99.6 %highlow lowcrucial-
deaths (time to event analysis only) 0.70 [0.40, 1.21]< 10%1 study (1/-)89.9 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.58 [0.36, 0.94]< 164%5 studies (5/-)98.7 %highnot evaluable lowimportant-
clinical improvement 1.17 [0.64, 2.13]> 112%2 studies (2/-)69.3 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 2.03 [0.17, 24.32]> 175%2 studies (2/-)71.0 %some concernnot evaluable moderateimportant-
clinical improvement (7-day) 1.91 [1.03, 3.53]> 10%1 study (1/-)98.0 %some concernnot evaluable moderateimportant-
death or ventilation 0.73 [0.57, 0.93]< 19%3 studies (3/-)99.5 %some concernnot evaluable moderateimportant-
hospital discharge 1.48 [1.05, 2.09]> 10%1 study (1/-)98.6 %some concernnot evaluable moderateimportant-
hospitalization 1.00 [0.14, 7.34]< 10%1 study (1/-)50.0 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.91 [0.51, 1.63]< 10%3 studies (3/-)62.2 %highnot evaluable lowimportant-
radiologic improvement (14-day) 2.87 [1.56, 5.28]> 10%1 study (1/-)100.0 %some concernnot evaluable moderateimportant-
viral clearance 1.61 [0.61, 4.25]> 182%3 studies (3/-)83.1 %some concernnot evaluable moderateimportant-
viral clearance (time to event analysis only) 0.81 [0.56, 1.18]> 10%1 study (1/-)13.7 %some concernnot evaluable moderateimportant-
viral clearance by day 14 0.18 [0.00, 435.69]> 198%2 studies (2/-)34.4 %some concernnot evaluable moderateimportant-
viral clearance by day 7 1.78 [0.91, 3.47]> 169%3 studies (3/-)95.4 %highnot evaluable lowimportant-
ICU admission 0.39 [0.12, 1.24]< 10%2 studies (2/-)94.5 %some concernnot evaluable moderatenon important-

safety endpoints 00

serious adverse events 0.73 [0.46, 1.16]< 10%4 studies (4/-)91.0 %some concernnot evaluable moderateimportant-
adverse events 1.51 [0.91, 2.52]< 10%3 studies (3/-)5.7 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.